# PranaX

> PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.

- **Founded:** 2024
- **Headquarters:** Houston, Texas, United States
- **Founders:** Dr. Steven J. Greco (Founder & Chief Operating Officer)
- **Team size:** ~14 employees
- **Products:** ExoWELL, ExoSTORE, Clinical exosome programs
- **Notable:** Secured exclusive MD Anderson license to exosome technology used in the first FDA-approved trial of mesenchymal stem cell-derived exosomes in cancer patients, Closed an oversubscribed $17M Series A financing (Feb 2026), Built a 7,400 sq ft FDA-registered cGMP exosome manufacturing facility at Levit Green, Houston

## Products & services

- **ExoWELL** — A physician-directed, GMP-manufactured stem cell exosome supplement for health and wellness, designed to modulate cellular function and promote tissue regeneration. The company's first commercial product.
- **ExoSTORE** — A personal exosome banking service offering collection and cryogenic storage of an individual's own exosomes from peripheral blood, umbilical cord blood, and neonatal tissues for future regenerative use.
- **Clinical exosome programs** — Development pipeline for exosome-based therapeutics targeting age-related chronic diseases, inflammation, and tissue degeneration, building on MD Anderson's licensed patent portfolio.

## Achievements

- Secured exclusive MD Anderson license to exosome technology used in the first FDA-approved trial of mesenchymal stem cell-derived exosomes in cancer patients
- Closed an oversubscribed $17M Series A financing (Feb 2026)
- Built a 7,400 sq ft FDA-registered cGMP exosome manufacturing facility at Levit Green, Houston
- Recruited former Lonza exosome business leader Phillip Maderia as CEO
- Underlying exosome technology published in Nature Communications

## Latest updates

- **2026-02** — Closed oversubscribed $17M Series A to expand R&D, infrastructure, partnerships, and product commercialization.
- **2026-01** — Exosome technology licensed to PranaX published in Nature Communications.
- **2025-03** — Appointed Phillip Maderia, former Lonza exosome business leader, as Chief Executive Officer (effective March 12, 2025).
- **2025-03** — Announced exclusive license of exosome technology from MD Anderson to commercialize stem cell exosomes.

## Links

- Website: https://pranax.com
- LinkedIn: https://www.linkedin.com/company/pranax
- Twitter/X: https://x.com/pranaxinc
- Instagram: https://www.instagram.com/pranaxinc/
- Facebook: https://www.facebook.com/Pranaxinc

---

Profile page: https://yespress.io/pranax
Published by YesPress — https://yespress.io
Last updated: 2026-07-18